Jesús
San Miguel Izquierdo
Consultor Investigador
Emory University School of Medicine
Atlanta, Estados UnidosPublicaciones en colaboración con investigadores/as de Emory University School of Medicine (8)
2023
-
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373
2021
-
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154
-
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2017
-
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051